FindTrial
Sign In

Population pharmacokinetic study of sodium valproate

Effects of genetic polymorphisms on sodium valproate concentration--a population pharmacokinetic study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058365
Enrollment
Unknown
Registered
2022-04-07
Start date
2020-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Population pharmacokinetics of sodium valproate

Interventions

Case series:No

Sponsors

Shanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 86 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years; 2. Patients who need antiepileptic treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with acute and chronic hepatitis; 2. Patients who use aspirin, traditional Chinese medicine, imipenem and meropenem at the same time; 3. Patients who have used valproic acid before and have no effect.

Design outcomes

Primary

MeasureTime frame
Blood Concentration of Sodium Valproate;—

Secondary

MeasureTime frame
height;Body weight;albumin;Alanine aminotransferase;Aspartate aminotransferase;Serum creatinine;rs1000940;rs1057910;rs1137101;rs12233719;rs12769205;rs17183814;rs1799853;rs1800012;rs1800497;rs2032582;rs2070959;rs2279020;rs2298771;rs2606345;rs2769605;rs28898617;rs3087374;rs3758581;rs3888190;rs4244285;rs4880;rs4986893;rs6759892;rs7439366;rs7668258;—

Countries

China

Contacts

Public ContactJiuhong Ma

Shanxi Provincial People's Hospital

mjh2003@163.com+86 15235198198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026